Fischer Medical Ventures Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 May 2026 | Healthcare Equipment & Supplies | Market Cap: ₹2.6K Cr
Fischer Medical Ventures targets a 15%-20% market share in the domestic and Asian MRI markets within 2-3 years, supported by a strong order book and favorable government policies. Fischer Medical Ventures expects to sustain growth aligned with the MedTech industry's macro growth rate of 15-20% CAGR, driven by government policies favoring Make-In-India and Atmanirbhar Bharat initiatives.
From Fischer Medical Ventures Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹38.1
Market Cap
₹2.6K Cr
P/E Ratio
104.7
Revenue Rank
Margin Rank
How does Fischer Medical Ventures Ltd rank in Healthcare Equipment & Supplies?
Compare Fischer Medical Ventures Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.
Fischer Medical Ventures Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹101 Cr, net profit ₹19 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Fischer Medical Ventures targets a 15%-20% market share in the domestic and Asian MRI markets within 2-3 years, supported by a strong order book and favorable government policies.
- →The total addressable market (TAM) for MRI devices in India is around 500 units per year, expected to grow over 1000 units annually in 3-4 years, driven by government health missions.
- →Growth is expected to be broad-based across Radiology (MRI and CT) and Preventive Healthcare segments, with revenue contribution expected to be almost equally split between these two in 2-3 years.
- →Company aims to leverage Make-In-India and Atmanirbhar Bharat initiatives along with import substitution to drive growth aligned with sector CAGR of 15%-20%.
- →Export markets are growing, contributing about 30% of revenues currently, up from about 5-10% a year ago, indicating international expansion potential.
- →Capacity can scale from 80 MRI machines/year (one shift) to about 150-160 machines/year (two shifts) to meet demand.
📈 Profitability & Margins
Rank 3- →Fischer Medical Ventures expects to sustain growth aligned with the MedTech industry's macro growth rate of 15-20% CAGR, driven by government policies favoring Make-In-India and Atmanirbhar Bharat initiatives.
- →Revenue split between Imaging and Preventive Healthcare segments is expected to become almost equal in 2-3 years, contributing significantly to overall growth.
- →The company highlights strong operating leverage and cost optimization strategies that have improved EBITDA margins notably (21% in the recent quarter).
- →While no explicit earnings guidance is provided, the company projects continued strong order books, especially in MRI machines, and revenue growth fueled by domestic and export markets.
- →PAT has improved tremendously (107x YoY in H1 FY '26), signaling profitability momentum likely to continue.
- →Expansion plans include scaling manufacturing capacity and entering CT and interoperable MRI markets, supporting future earnings growth.
- →The company avoids providing specific forward-looking profit or EPS numbers but indicates confident growth prospects in line with sector trends.
🏗️ Capital Expenditure Plans
Yes- →Current manufacturing capacity: About 80 MRI machines per year in one shift; can be increased to 150-160 with two shifts.
- →Facility expansion plans underway: Expansion of manufacturing facility to include other imaging lines such as CT scanners.
- →Preventive healthcare capacity expansion: Focus on people (AI, software development) and server infrastructure rather than hardware manufacturing.
- →Supply chain and regulatory focus: Continued efforts on obtaining international regulatory approvals for exports; current emphasis remains on domestic market.
- →No specific capex amounts disclosed, but expansion and capacity scaling are actively planned and in process, including brownfield expansion options.
- →Plans to scale AI and tele-diagnostic solutions as part of preventive healthcare ecosystem development.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
Yes- →Fischer Medical Ventures has a strong order book currently.
- →Orders are being fulfilled as and when they arise, especially in the MRI segment.
- →The sales cycle for MRI machines ranges from 6 to 9 months, sometimes up to 12 months.
- →The company expects good order inflow for the rest of H2 FY '26 and into the next year.
- →Exact figures of the backlog are not disclosed due to customer confidentiality.
- →Overall, the company is confident about fulfilling a robust order book through the near term.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Fischer Medical Ventures Ltd Q2 FY26 results?
Fischer Medical Ventures targets a 15%-20% market share in the domestic and Asian MRI markets within 2-3 years, supported by a strong order book and favorable government policies. Fischer Medical Ventures expects to sustain growth aligned with the MedTech industry's macro growth rate of 15-20% CAGR, driven by government policies favoring Make-In-India and Atmanirbhar Bharat initiatives.
What is Fischer Medical Ventures Ltd share price analysis?
Fischer Medical Ventures Ltd currently shows a below-average growth signal. The stock trades at a P/E of 104.7 with a market cap of ₹2,564 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fischer Medical Ventures Ltd planning capital expenditure?
Current manufacturing capacity: About 80 MRI machines per year in one shift; can be increased to 150-160 with two shifts.
Keep Fischer Medical Ventures Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.